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Interviews conducted in South Africa found that awareness of antiretroviral 
therapy was generally poor. Antiretroviral drugs were not perceived as new, 
but one of many alternative therapies for HIV/AIDS. Respondents had more 
detailed knowledge of indications, effects and how to access alternative 
treatments, which is bolstered by the active promotion and legitimization of 
alternative treatments. Many expressed a lack of excitement about the 
introduction of antiretroviral therapy, and little change in their attitudes 
concerning the epidemic. 
The introduction of HIV treatment in developed countries has been credited with reducing 
the denial, stigma and discrimination of HIV/AIDS as a disease [1]. In South Africa the 
introduction of antiretroviral drugs seems to have had a limited effect on high levels of 
stigma [2], risk behaviour [3] and HIV incidence [4]. We set out to examine the potential 
cause of this lack of a wider effect especially with respect to the influence of other treatment 
options. 
We conducted a total of 197 interviews across three districts where antiretroviral therapy 
had been introduced for at least 6 months. Interviews were conducted in three populations: 
76 individuals on antiretroviral therapy, 58 HIV-positive women not taking antiretroviral 
drugs, 45 community members, and 18 community gate-keepers such as leaders of 
non-governmental organizations, health workers and representatives from local 
government. 
Respondents were interviewed using pretested semi-structured guides. Transcripts were 
reviewed daily by site supervisors to identify emerging themes and ensure quality. 
Interviews were analysed through the systematic identification and coding of themes. The 
results were then discussed and consensus was reached in two analysis workshops by all 
authors. Ethical approval was granted by the University of the Western Cape and Tulane 
University. 
Only seven of the 33 community respondents who had heard of antiretroviral agents 
reported them as a factor influencing the lifespan of a person with HIV, and only 10 reported 
antiretroviral treatment as a benefit of having an HIV test. Some explicitly expressed a lack 
of excitement about antiretroviral therapy: 'When I asked if he had heard of the new HIV 
medication he looked excited and said ''no''. ... As soon as I mentioned the word ARVs he 
said ''oh those'' and seemed to lose interest. ... I asked if people were excited about the 
provision of ARVs, he said ''no they are nothing new, because they have said they are not 
curing, it's still the same''.' (Community leader). A lack of excitement was also expressed by 
health workers: 'They (nurses in community clinics) just see it as another thing they have to  
 
do.' (Antiretroviral therapy nurse). Excitement was higher among the HIV-positive 
respondents: they reported that being on antiretroviral drugs had improved their health and 
given them hope, and nearly all of the 28 HIV-positive women who had heard of 
antiretroviral treatment reported that they would like to be on therapy at some point; 
however, only eight of the women had tried or were in the process of trying to access 
treatment. 
All respondent groups reported that antiretroviral drugs were not a new class of treatment 
but, along with 21 other mass-produced 'immune boosters' also listed, were classified as 
boosting a person's 'body soldiers' (immune system); antiretroviral agents were, however, 
seen as particularly strong and powerful. Almost half (40%) of the antiretroviral therapy 
respondent group reported that they had used one or more of the alternative treatments 
before starting antiretroviral therapy. 
Alternative treatments were popular despite their cost, which, for some respondents, 
consumed a large proportion of their income. We found several reasons why alternative 
treatment was more attractive. Many of the alternative treatments have been available for 
many years and knowledge of them is much greater than knowledge of antiretroviral drugs as 
regards details such as where to access them and how to take them. 
Manufacturers and sellers of alternative treatments have adopted strong and successful 
marketing strategies, whereas antiretroviral therapy awareness activities are relatively low 
key and are focused on providing factual information rather than on a hard sell (Table 1). 
Alternative treatments have been legitimized through several routes (Table 1), and there is a 
strong belief that they are efficacious. Because many of the alternative treatments are not 
specifically targeted towards HIV they can be used without disclosure or stigmatization, and 
before formal testing. 
Finally, alternative treatments are widely distributed, do not require a long wait or a 
prescription, and can be accessed regardless of the stage of the illness. Antiretroviral drugs 
were available free of charge in all sites but there is a lengthy enrolment process. 
Antiretroviral drugs were perceived as being only for the critically ill, and the HIV- positive 
respondents reported using alternative treatments when they (or health staff) did not 
consider themselves sick enough for antiretroviral drugs or had difficulty accessing them: 
'He asked the nurse about ARVs. . .. The nurse said he is still strong and he can survive and 
advised him to seek traditional medicines. He went to a traditional healer that he had heard 
about in the community. . .. He paid R500 and lived at the traditional healer's for some time 
so that he could take the medicines well.' (Antiretroviral therapy respondent). 





Antiretroviral therapies are being introduced into a complex HIV treatment environment where 
they are competing with a multitude of alternative treatments. The choices are overwhelming 
and range from age old indigenous 'cure-alls' to new herbal 'boosters'. Respondents across all 
three sites had more detailed knowledge of the indications, effects and how to access these 
alternative treatments than they did of antiretroviral drugs. This is being bolstered by the 
promotion and legitimization of alternative treatments and the contrasting lack of similar 
activities for antiretroviral therapy. 
There could be some selection bias in this study as neither the three sites nor the respondents 
were randomly selected. However, each of the three sites is representative of most of the 
different types of contexts seen across South Africa, and a relatively large number of respondents 
with a range of different characteristics were interviewed for this study. 
The relatively poor acknowledgement, by senior politicians, state authorities, widely publicized 
'experts' and members of the community, of the positive effects of antiretroviral drugs and the 
concomitant lack of excitement among those not already on treatment may impair both 
individual adherence to treatment and the possible HIV prevention benefits of antiretroviral 
treatment. A more explicit communication strategy that promotes the benefits of antiretroviral 
therapy is required. If antiretroviral agents are to compete more successfully in the therapeutic 
continuum, there needs to be explicit recognition of, and further strategies to counter, the 
attraction of alternative therapies for patients and the systematic promotion these treatments 
receive, including from professional health workers. 
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